文献速递甲状腺疾病

2004-2016年韩国儿童甲状腺癌发病率、治疗及临床病程趋势:全国性人群研究

Trends in Pediatric Thyroid Cancer Incidence, Treatment, and Clinical Course in Korea During 2004-2016: A Nationwide Population-Based Study.
PubMed 文献 · Thyroid · 2020-12-04

该研究基于韩国国家健康信息数据库,分析2004-2016年1580例20岁以下甲状腺癌患者。年龄标化发病率从0.6/10万增至0.9/10万,平均年百分比变化4.0%。腺叶切除率和淋巴结清扫率上升,放射性碘治疗率下降;初始手术+放射性碘治疗组中0-14岁患者新治疗事件风险高于18-19岁(HR 2.5)。

要点

  • 儿童甲状腺癌年龄标化发病率从0.6/10万升至0.9/10万,平均APC 4.0%。
  • 腺叶切除率从18.5%升至33.6%,淋巴结清扫率从29.6%升至84.5%,放射性碘治疗率从67.9%降至39.7%。
  • 初始手术+放射性碘治疗组中0-14岁患者新治疗事件风险高于18-19岁(HR 2.5)。

核心结论

  • 2004-2012年韩国儿童甲状腺癌发病率上升。
  • 腺叶切除和淋巴结清扫率增加,放射性碘治疗率下降。
  • 初始需放射性碘治疗的15岁以下患者新治疗事件风险较高,可能与诊断时分期较晚有关,需进一步评估。

研究设计与样本

  • 基于韩国国家健康信息数据库的全国性人群研究,纳入2004-2016年诊断的1580例20岁以下甲状腺癌患者(男性324例)。
  • 采用joinpoint回归分析计算年龄标化发病率的年度百分比变化(APC)。
  • 初始治疗分为单纯手术和手术+放射性碘治疗,新治疗事件定义为再次手术或额外放射性碘治疗,在1464例随访≥12个月的患者中评估。

主要发现

  • 年龄标化发病率从0.6/10万(CI 0.5-0.8)升至0.9/10万(CI 0.8-1.1),平均APC 4.0%(CI 1.8-6.2)。
  • 0-9岁、10-14岁、15-17岁、18-19岁年龄组ASR分别为0.07、0.6、2.2、4.2/10万,APC分别为9.9%(CI 0.08-20.7)、4.6%(CI 0.2-9.2)、3.9%(CI 1.7-6.0)、3.5%(CI 0.9-6.2)。
  • 腺叶切除率从18.5%升至33.6%(p=0.0014),淋巴结清扫率从29.6%升至84.5%(p<0.001),放射性碘治疗率从67.9%降至39.7%(p<0.001)。
  • 中位随访6.3年,2例死亡;单纯手术组(n=523)56例(10.7%)发生新治疗事件;手术+放射性碘治疗组(n=941)中316例在2年内接受≥2次放射性碘治疗,剩余625例中80例(12.8%)发生新治疗事件。
  • 手术+放射性碘治疗亚组中,0-14岁患者无事件生存率低于18-19岁患者(HR 2.5,CI 1.4-4.4)。

临床怎么用

  • 儿童甲状腺癌发病率呈上升趋势,临床需关注年龄较小患者的长期随访。
  • 初始需放射性碘治疗的15岁以下患者新治疗事件风险较高,应加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The incidence of thyroid cancer has increased worldwide. We investigated nationwide trends in the incidence and treatment course of pediatric thyroid cancer in South Korea. Methods: Using the National Health Information Database, we analyzed 1580 patients (324 males) <20 years of age diagnosed with thyroid cancer during 2004-2016 in South Korea. The annual percentage change (APC) in the age-standardized incidence rate (ASR) was calculated by joinpoint regression analysis. The initial treatment modality was categorized as either surgery only or surgery with radioactive-iodine treatment (surgery+RAIT), and we defined new treatment events as reoperations or additional RAITs among 1464 patients followed up for ≥12 months. Results: During 2004-2016, the mean ASR per 100,000 person-years increased from 0.6 [confidence interval; CI 0.5-0.8] to 0.9 [CI 0.8-1.1], with a mean APC of 4.0% [CI 1.8-6.2]. The ASRs (APCs) among 0-9-, 10-14-, 15-17-, and 18-19-year olds were 0.07 (9.9% [CI 0.08-20.7]), 0.6 (4.6% [CI 0.2-9.2]), 2.2 (3.9 [CI 1.7-6.0]), and 4.2 (3.5% [CI 0.9-6.2]), respectively. The lobectomy and lymph-node-dissection rates increased (from 18.5% to 33.6%, p = 0.0014; and from 29.6% to 84.5%, p < 0.001; respectively), but the RAIT rate decreased (67.9-39.7%, p < 0.001) during the study period. During a median 6.3-year follow-up, two patients died. New treatment events occurred in 56 (10.7%) of patients in the initial surgery-only group (n = 523). In the initial surgery+RAIT group (n = 941), 316 patients received two or more RAITs within 2 years, and 80 (12.8%) of the remaining 625 patients underwent new treatment events. In the surgery+RAIT subgroup, the event-free survival rate was lower in 0-14-year olds than in 18-19-year olds (hazard ratio 2.5 [CI 1.4-4.4]). Conclusions: The pediatric thyroid cancer incidence increased from 2004 to 2012 in South Korea. The lobectomy and lymph-node-dissection rates increased, but the RAIT rate decreased. The higher risk for new treatment events in patients younger than 15 years requiring initial RAIT may be linked to advanced stage at diagnosis, and it needs to be further evaluated.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lee YA, Yun HR, Lee J, et al. Trends in Pediatric Thyroid Cancer Incidence, Treatment, and Clinical Course in Korea During 2004-2016: A Nationwide Population-Based Study. Thyroid. 2020. PMID: 33107409. doi:10.1089/thy.2020.0155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。